Description of discordance over time in patients with early axSpA
| Baseline N=702 | 6 months follow-up N=633 | 12 months follow-up N=600 | 18 months follow-up N=542 | 24 months follow-up N=566 | 36 months follow-up N=513 | |
|---|---|---|---|---|---|---|
| PGA, mean (SD) | 5.1 (2.6) | 4.0 (2.7) | 4.2 (2.7) | 3.9 (2.7) | 3.9 (2.7) | 3.8 (2.7) |
| PhGA, mean (SD) | 4.3 (2.2) | 3.2 (2.3) | 3.2 (2.3) | 2.8 (2.1) | 2.9 (2.2) | 2.8 (2.2) |
| |PGA−PhGA|, mean (SD)* | 1.8 (1.6) | 1.7 (1.6) | 1.8 (1.7) | 1.7 (1.6) | 1.8 (1.7) | 1.7 (1.6) |
| Discordance, N (%) | ||||||
| |PGA−PhGA|≥3 | 202 (28.8) | 168 (26.5) | 163 (27.2) | 138 (25.5) | 162 (28.6) | 137 (26.7) |
| |PGA−PhGA|≥2 | 335 (47.7) | 281 (44.4) | 270 (45.0) | 248 (45.8) | 281 (49.7) | 234 (45.6) |
| Higher patient rating group, N (%) | ||||||
| |PGA−PhGA|≥3 | 151 (21.5) | 139 (22.0) | 142 (23.7) | 125 (23.1) | 137 (24.2) | 116 (22.6) |
| |PGA−PhGA|≥2 | 237 (33.8) | 209 (33.0) | 223 (37.2) | 203 (37.5) | 224 (39.6) | 188 (36.7) |
| Lower patient rating group, N (%) | ||||||
| |PGA−PhGA|≥3 | 51 (7.3) | 29 (4.6) | 21 (3.5) | 13 (2.4) | 25 (4.4) | 21 (4.1) |
| |PGA−PhGA|≥2 | 98 (14.0) | 72 (11.4) | 47 (7.8) | 45 (8.3) | 57 (10.1) | 46 (9.0) |
The N indicated in the title line is the number of patients with PGA and PhGA available at that time point.
*The difference PGA and PhGA was significant at each time point (p<0.001).
axSpA, axial spondyloarthritis; PGA, patient global assessment; PhGA. physician global assessment.